Bamco Inc. NY Reduces Stock Position in DexCom, Inc.

Institutional investor trims stake in medical device company

Mar. 16, 2026 at 8:19am

Got story updates? Submit your updates here. ›

Bamco Inc. NY, an investment management firm, decreased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 18.0% during the third quarter, according to a recent SEC filing. The firm previously owned 272,500 shares of the medical device company's stock, but sold 60,000 shares during the period.

Why it matters

DexCom is a leading manufacturer of continuous glucose monitoring (CGM) systems, which are important medical devices for people with diabetes. Changes in institutional ownership of DexCom stock can signal shifts in investor sentiment and market expectations for the company.

The details

According to the filing, Bamco Inc. NY now owns about 0.07% of DexCom's outstanding shares, down from a previous stake of 0.09%. The firm cited unspecified reasons for reducing its position in the medical device company. DexCom's stock price has fluctuated in recent months, trading between $54.11 and $89.98 over the past 52 weeks.

  • Bamco Inc. NY reduced its DexCom holdings during the third quarter of the year.

The players

Bamco Inc. NY

An investment management firm that previously held a stake in DexCom, Inc.

DexCom, Inc.

A medical device company that develops and manufactures continuous glucose monitoring systems for people with diabetes.

Got photos? Submit your photos here. ›

The takeaway

This filing indicates that one institutional investor has reduced its position in DexCom, though the reasons behind the move are unclear. Investors will likely continue to monitor changes in ownership and sentiment around this key player in the diabetes technology market.